Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma

Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.